Cell Transitions Contribute to Glucocorticoid-Induced Bone Loss

Cells. 2023 Jul 8;12(14):1810. doi: 10.3390/cells12141810.

Abstract

Glucocorticoid-induced bone loss is a toxic effect of long-term therapy with glucocorticoids resulting in a significant increase in the risk of fracture. Here, we find that glucocorticoids reciprocally convert osteoblast-lineage cells into endothelial-like cells. This is confirmed by lineage tracing showing the induction of endothelial markers in osteoblast-lineage cells following glucocorticoid treatment. Functional studies show that osteoblast-lineage cells isolated from glucocorticoid-treated mice lose their capacity for bone formation but simultaneously improve vascular repair. We find that the glucocorticoid receptor directly targets Foxc2 and Osterix, and the modulations of Foxc2 and Osterix drive the transition of osteoblast-lineage cells to endothelial-like cells. Together, the results suggest that glucocorticoids suppress osteogenic capacity and cause bone loss at least in part through previously unrecognized osteoblast-endothelial transitions.

Keywords: bone loss; endothelial-like cells; glucocorticoid; osteoblast; transition.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Animals
  • Bone Diseases, Metabolic*
  • Glucocorticoids* / adverse effects
  • Mice
  • Osteoblasts
  • Osteogenesis

Substances

  • Glucocorticoids